Update on Cytokinetics BENEFIT-ALS

April 29, 2014

Today, Cytokinetics, Incorporated announced additional results from its BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS), which will be presented later today during the 66th Annual Meeting of the American Academy of Neurology (AAN) conference in Philadelphia.

Read the press release from Cytokinetics.

Powered by Blackbaud
nonprofit software